A new study published in The Lancet Microbe reports that the first twice-yearly injectable HIV treatment regimen – the combination of lencapavir, teropavimab and zinlirivimab – achieved high rates of viral suppression and demonstrated a favorable safety profile at 26 weeks. Led by Joe Aron, MD, a researcher at the UNC Institute for Global Health and Infectious Diseases, the findings are an important milestone toward what could become the first complete long-acting HIV regimen requiring dosing only twice per year.
Please follow and like us:
